Quarterly ResultMay 12, 2026, 04:04 PM
Kura Oncology Q1 Net Product Revenue $5.8M; Net Loss $73.3M
AI Summary
Kura Oncology reported its first quarter 2026 financial results, with KOMZIFTI generating $5.8 million in net product revenue in its first full quarter of commercialization. The company saw robust early launch dynamics, including 85 new patient starts and over 93% payer coverage. Despite increased R&D and SG&A expenses, leading to a net loss of $73.3 million, Kura Oncology maintains a strong cash position of $580.8 million, expected to fund its ziftomenib AML program through Phase 3 results.
Key Highlights
- KOMZIFTI net product revenue was $5.8 million in its first full quarter of commercialization.
- Total revenue for Q1 2026 was $18.3 million, up from $14.1 million in Q1 2025.
- Research and development expenses increased to $65.3 million from $56.0 million YoY.
- Selling, general and administrative expenses rose to $31.6 million from $22.8 million YoY.
- Net loss for Q1 2026 was $73.3 million, compared to $57.4 million in Q1 2025.
- Cash, cash equivalents, and short-term investments totaled $580.8 million as of March 31, 2026.
- The company reported 85 new patient starts and 157 total prescriptions for KOMZIFTI.
- Payer coverage for KOMZIFTI reached over 93%, covering more than 12 million lives.